Compounds useful as inhibitors of atr kinase

A compound of formula I:

• or a pharmaceutically acceptable salt or prodrug thereof, wherein:
• R7 and R8, together with the atoms to which they are joined, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms independently selected from oxygen, nitrogen, or sulfur;
• the ring formed by R7 and R8 is optionally substituted with 0-3 occurrences of R1;
• R1 is independently selected from halo, CN, a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-2 heteroatoms independently selected from oxygen, nitrogen or sulfur;
• or a C1-6aliphatic chain wherein up to three methylene units are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• R1 is optionally substituted with 0-3 occurrences of J1;
• J1 is independently selected from halo, —CN, a C1-4alkyl, or a 3-6 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-1 heteroatoms selected from oxygen, nitrogen, or sulfur;
• A is independently selected from:
• R3 is independently selected from -(L)n-Q1 or T;
• L and T are each independently a C1-10aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—, each L and T is independently substituted with 0-5 occurrences of JLT;
• JLT is independently selected from —CN, halo, or a C1-4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• n is 0 or 1;
• Q1 is independently selected from a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen or sulfur;
• or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur;
• wherein Q1 is independently substituted with 0-5 occurrences of JQ;
• JQ is independently selected from —CN;
• halo;
• ═O;
• Q2;
• or a C1-8aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• each occurrence of JQ is optionally substituted by 0-3 occurrences of JR;
• or
• two occurrences of JQ on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
• wherein the ring formed by two occurrences of JQ is optionally substituted with 0-3 occurrences of JX;
• or
• two occurrences of JQ, together with Q1, form a 6-10 membered saturated or partially unsaturated bridged ring system;
• Q2 is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen, or sulfur;
• or a 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur
• JR is independently selected from —CN;
• halo;
• ═O;
• →O;
• Q3;
• or a C1-6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• each JR is optionally substituted with 0-3 occurrences of JP;
• or
• two occurrences of JR on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
• wherein the ring formed by two occurrences of JR is optionally substituted with 0-3 occurrences of JX;
• or
• two occurrences of JR, together with Q2, form a 6-10 membered saturated or partially unsaturated bridged ring system;
• Q3 is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen, or sulfur;
• or a 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur;
• JX is independently selected from —CN;
• halo or a C1-4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• or
• JP is independently selected from —CN;
• halo;
• ═O;
• a C1-6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
• JP is optionally substituted with 0-3 occurrences of JM;
• or
• two occurrences of JP on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;
• or
• two occurrences of JP, together with Q3, form a 6-10 membered saturated or partially unsaturated bridged ring system;
• R4 is independently selected from H;
• halo;
• C1-4alkyl optionally substituted with 1-3 occurrences of halo;
• C3-4cycloalkyl;
• 3-4 membered heterocyclyl;
• —CN;
• or a C1-3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• R5 is independently selected from H;
• halo;
• 3-4 membered heterocyclyl;
• —CN;
• a C1-2alkyl optionally substituted with 0-3 occurrences of fluoro;
• or a C1-3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• R6 is independently selected from H, halo, C3-4cycloalkyl, 3-4 membered heterocyclyl, or C1-3aliphatic wherein up to two methylene units of the aliphatic chain are optionally replaced with —O—, —NR—, —C(O)—, or —S(O)z—;
• JM is independently selected from halo or C1-6aliphatic:
• z is 0, 1 or 2;
• and
• R is independently selected from H or C1-4aliphatic.